TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
ImmunoIVD AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
5,073
|
4,437
|
3,807 |
| Financial expenses |
132
|
152
|
142 |
| Earnings before taxes |
1,167
|
397
|
500 |
| EBITDA |
1,450
|
723
|
861 |
| Total assets |
3,703
|
2,964
|
2,807 |
| Current assets |
3,180
|
2,403
|
2,253 |
| Current liabilities |
2,137
|
2,237
|
2,168 |
| Equity capital |
1,567
|
727
|
639 |
| - share capital |
9
|
9
|
9 |
| Employees (average) |
27
|
25
|
23 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
42.3%
|
24.5%
|
22.8% |
| Turnover per employee |
188
|
177
|
166 |
| Profit as a percentage of turnover |
23.0%
|
8.9%
|
13.1% |
| Return on assets (ROA) |
35.1%
|
18.5%
|
22.9% |
| Current ratio |
148.8%
|
107.4%
|
103.9% |
| Return on equity (ROE) |
74.5%
|
54.6%
|
78.2% |
| Change turnover |
787
|
619
|
635 |
| Change turnover % |
18%
|
16%
|
20% |
| Chg. No. of employees |
2
|
2
|
-3 |
| Chg. No. of employees % |
8%
|
9%
|
-12% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.